FARP1 mediates cMET-driven motility in androgen-independent prostate cancer cells
Endocrinology · 26.05.2026 · 167 (7)
DOI: 10.1210/endocr/bqag062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 23.05.2026. Verfasst von Paola Robayo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA. Hauptthemen laut MEDLINE: Cell Movement, Prostatic Neoplasms, Proto-Oncogene Proteins c-met, Rho Guanine Nucleotide Exchange Factors. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCI Cancer Center Support Grant, University of Miami Miller School of Medicine.
Abstract (Originalsprache)
Activation of Rac1, a member of the Rho family of small GTPases and a well-established downstream effector of receptor tyrosine kinases (RTKs), has been linked to prostate cancer progression and predicts poor progression in prostate cancer patients. Rac1 and its upstream activators, the Rac guanine nucleotide exchange factors (Rac-GEFs), act as key drivers for RTK-mediated formation of actin-rich protrusions, structures involved in cancer cell motility and invasion. Our previous study identified VAV2 as the main Rac-GEF effector of epidermal growth factor receptor in androgen-independent cellular models. An unbiased RNAi screen targeting Rac-GEFs as effectors of cMET, which is an RTK frequently overexpressed in castration-resistant prostate cancer and associated with invasion and metastasis, identified the Rac-GEF FARP1 (FERM, ARH/RhoGEF and Plekstrin Domain Protein 1) as a pivotal contributor to Rac1-mediated migration and invasion. Notably, stimulation of cMET with its ligand Hepatocyte Growth Factor (HGF) promotes the formation of actin-rich protrusions through a PI3K-FARP1-Rac1-dependent pathway and independently of VAV2. Furthermore, FARP1 relocalizes to actin-rich protrusions in PC3 cells in response to HGF stimulation. Our results shed light on the distinctive contribution of Rac-GEFs to prostate cancer cell motility via RTKs and identify FARP1 as a crucial cMET-invasive effector. The differential coupling of RTKs to Rac-GEFs underscores the complexities of signaling events leading to Rac1 activation. It provides insight into the RTK effectors that contribute to prostate cancer cell invasiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
- Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA.
- Manchester Cancer Research Centre (MCRC), Division of Cancer Sciences, University of Manchester, Manchester M20 4GJ, UK.
ORCID-Profile: Marcelo G Kazanietz, Mariana Cooke
Förderung
- NCI NIH HHS
- NCI Cancer Center Support Grant
- University of Miami Miller School of Medicine
- Sylvester Comprehensive Cancer Center
Zitieren
APA
Robayo, P., Kazanietz, M. G., Baker, M. J., & Cooke, M. (2026). FARP1 mediates cMET-driven motility in androgen-independent prostate cancer cells. Endocrinology, 167(7). https://doi.org/10.1210/endocr/bqag062
Vancouver
Robayo P, Kazanietz MG, Baker MJ, Cooke M. FARP1 mediates cMET-driven motility in androgen-independent prostate cancer cells. Endocrinology. 2026;167(7). doi:10.1210/endocr/bqag062
BibTeX
@article{Robayo2026,
author = {Robayo, Paola and Kazanietz, Marcelo G and Baker, Martin J and Cooke, Mariana},
title = {FARP1 mediates cMET-driven motility in androgen-independent prostate cancer cells},
journal = {Endocrinology},
year = {2026},
volume = {167},
number = {7},
doi = {10.1210/endocr/bqag062}
}
EUVIMED